Matusz-Fisher Ashley, Chen Annabel, Donahue Erin E, Schepel Courtney R, Wallander Michelle L, Livasy Chad A, White Richard L, Tan Antoinette R, Hadzikadic-Gusic Lejla
Department of Solid Tumor Oncology and Investigational Therapeutics, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Atrium Health Levine Cancer, Wake Forest University School of Medicine, Charlotte, NC.
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Clinical Trials Office, Atrium Health Levine Cancer, Charlotte, NC.
Clin Breast Cancer. 2025 May 3. doi: 10.1016/j.clbc.2025.04.022.
Metaplastic breast cancer (MpBC) is a rare, aggressive type of breast cancer composed of several histologic patterns. This study evaluated outcomes among the MpBC histologic patterns, which include spindle cell/sarcomatous, squamous, heterologous mesenchymal, and mixed.
A retrospective chart review identified patients with early-stage MpBC diagnosed between January 1, 2010, and September 1, 2021. A matched control patient cohort with nonmetaplastic triple-negative breast cancer (TNBC) was selected. Associations between MpBC histologic patterns and disease characteristics were evaluated using chi-squared and Wilcoxon tests. Kaplan-Meier estimates and log rank tests assessed differences in recurrence-free survival (RFS) and overall survival (OS).
In the MpBC cohort (n = 106), histologic patterns included spindle cell/sarcomatous (34%), squamous (16%), heterologous mesenchymal (31%), mixed (18%), and other (1%). In patients with MpBC who received neoadjuvant chemotherapy (n = 32), residual cancer burden (RCB) was not found to be significantly different between the spindle cell/sarcomatous pattern versus other patterns (P = .81). In the entire MpBC cohort, patients with the spindle cell/sarcomatous pattern had inferior RFS (P = .02) and OS (P = .004) compared to patients with other patterns. There was no significant difference in RFS (P = .90) or OS (P = .90) between the MpBC and TNBC cohort.
RCB did not differ among the MpBC histologic patterns, but outcomes were inferior in patients with the spindle cell/sarcomatous pattern. Outcomes were also inferior in patients with MpBC receiving neoadjuvant versus adjuvant chemotherapy. Our study did not find a difference in outcomes between patients with MpBC versus nonmetaplastic TNBC. More investigation with larger sample sizes and biomarkers is warranted.
化生性乳腺癌(MpBC)是一种罕见的侵袭性乳腺癌,由多种组织学模式组成。本研究评估了MpBC组织学模式(包括梭形细胞/肉瘤样、鳞状、异源性间叶性和混合型)的预后情况。
一项回顾性病历审查确定了2010年1月1日至2021年9月1日期间诊断为早期MpBC的患者。选取了非化生性三阴性乳腺癌(TNBC)患者作为匹配对照队列。使用卡方检验和威尔科克森检验评估MpBC组织学模式与疾病特征之间的关联。采用Kaplan-Meier估计法和对数秩检验评估无复发生存期(RFS)和总生存期(OS)的差异。
在MpBC队列(n = 106)中,组织学模式包括梭形细胞/肉瘤样(34%)、鳞状(16%)、异源性间叶性(31%)、混合型(18%)和其他(1%)。在接受新辅助化疗的MpBC患者(n = 32)中,梭形细胞/肉瘤样模式与其他模式之间的残余癌负担(RCB)无显著差异(P = 0.81)。在整个MpBC队列中,与其他模式的患者相比,梭形细胞/肉瘤样模式的患者RFS较差(P = 0.02),OS也较差(P = 0.004)。MpBC队列和TNBC队列之间的RFS(P = 0.90)或OS(P = 0.90)无显著差异。
MpBC组织学模式之间的RCB无差异,但梭形细胞/肉瘤样模式的患者预后较差。接受新辅助化疗的MpBC患者的预后也较差。我们的研究未发现MpBC患者与非化生性TNBC患者的预后存在差异。需要进行更大样本量和生物标志物的更多研究。